Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 8/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868044 | 0.91 | TBXAS1 (0.60) | TBXAS1TDP1L3MBTL1CYP2A6NAPRT | |
| Hydrochloric Acid SCHEMBL11004443 | 0.89 | TBXAS1 (0.61) | TBXAS1TDP1L3MBTL1NAPRTCHRNA7 | |
| SCHEMBL30612524 | 0.86 | TBXAS1 (0.90) | TBXAS1TDP1L3MBTL1CYP2A6HRH1 | |
| SCHEMBL933853 | 0.86 | TBXAS1 (0.68) | TBXAS1TDP1L3MBTL1CYP2A6HRH1 | |
| SCHEMBL1583762 | 0.86 | TBXAS1 (0.90) | TBXAS1TDP1L3MBTL1CYP2A6HRH1 | |
| SCHEMBL9522811 | 0.86 | TDP1 (0.61) | TBXAS1TDP1L3MBTL1CYP2A6HRH1 | |
| SCHEMBL9520246 | 0.85 | TBXAS1 (0.62) | TBXAS1TDP1L3MBTL1CYP2A6HRH1 | |
| SCHEMBL20221007 | 0.84 | TBXAS1 (0.66) | TBXAS1TDP1L3MBTL1CYP2A6HRH1 | |
| SCHEMBL5724822 | 0.84 | TBXAS1 (0.66) | TBXAS1TDP1L3MBTL1CYP2A6HRH1 | |
| SCHEMBL19176893 | 0.83 | TBXAS1 (0.60) | TBXAS1TDP1L3MBTL1CYP2A6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3169666-B1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| WO-2016008582-A1 | SUBSTITUTED AZASPIRO(4.5)DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
| EP-2569629-B1 | DETECTION OF NICOTINE METABOLITES | GFC DIAGNOSTICS LTD (GB) | 2015-08-19 | — | — | EP | disclosed |
| US-6534489-B1 | Organophosphorus compounds and the use thereof | JOMAA PHARMAKA GMBH (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-1133500-B1 | ORGANOPHOSPHOROUS COMPOUNDS AND THE USE THEREOF | JOMAA PHARMAKA GMBH (DE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1133500-A1 | ORGANOPHOSPHOROUS COMPOUNDS AND THE USE THEREOF | Jomaa Pharmaka GmbH (DE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000031085-A1 | ORGANOPHOSPHOROUS COMPOUNDS AND THE USE THEREOF | JOMAA PHARMAKA GMBH (DE) | 2000-06-02 | — | — | WO | disclosed |
| WO-1997021703-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| EP-0299379-B1 | PENTADIENAMIDE PAF-ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1993-04-21 | — | — | EP | disclosed |
| US-4975438-A | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. (US) | 1990-12-04 | — | — | US | disclosed |
| US-4927838-A | CARDIOVASCULAR DISORDERS | HOFFMAN-LA ROCHE INC. (US) | 1990-05-22 | — | — | US | disclosed |
| US-4927826-A | Cycloproylpropenamides useful as platelet activing factor (PAF) antagonists | HOFFMAN-LA ROCHE INC. (US) | 1990-05-22 | — | — | US | disclosed |
| US-4916145-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 1990-04-10 | — | — | US | disclosed |
| EP-0299379-A1 | Pentadienamide PAF-antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-18 | — | — | EP | disclosed |
| EP-0298466-A2 | Substituted alkene carboxylic acid amides and derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-11 | — | — | EP | disclosed |
| US-4788206-A | CARDIOVASCULAR DISORDERS, PLATELETS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4786646-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | TBXAS1 1327/4885TDP1 4487/4885L3MBTL1 3149/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | TBXAS1 465/4885TDP1 3252/4885L3MBTL1 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.